Immunowake, Inc.

Immunowake, Inc. is a private, pre-clinical stage biotechnology company focused on cancer drug discovery. The company's strategy involves harnessing the body’s immune system to identify and kill cancer cells, similar to the way pathogens are targeted. Recent breakthroughs in cancer immunotherapy have shown that activating antigen-specific T-cells can lead to powerful anti-tumor responses.

Founded in 2019 and headquartered in the United States, Immunowake recently received a $20.00M Series A investment on May 15, 2022. The investment was made by Hyfinity Investments, South China VC, Lapam Capital, and HEDA VENTURES.